Epidermal growth factor receptor pathway inhibition in ACC has yielded disappointing results, likely owing to the low rate of EGFR mutations in ACC, and EGFR inhibitors are no longer being investigated in ACC. Here, EGFR is linked to adrenal cortex carcinoma.